9.36  0.41 (4.58%)		05-13 16:00
Open: 8.96 High: 9.46 Volume: 815,500		Pre. Close: 8.95 Low: 8.8 Market Cap: 509(M)

Short term
Mid term
Targets	6-month :	11.57	1-year :	12.46
Resists	First :	9.91	Second :	10.66
Pivot price	9.23
Supports	First :	8.68	Second :	7.23
MAs	MA(5) :	9.09	MA(20) :	9.37
	MA(100) :	16.46	MA(250) :	17.17
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	40.3	D(3) :	31.1
RSI	RSI(14): 47.8
52-week	High :	33.68	Low :	7.25

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ UPB ] has closed below upper band by 32.8%. Bollinger Bands are 90.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 48 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	9.47 - 9.51	9.51 - 9.55
Low:	8.69 - 8.74	8.74 - 8.79
Close:	9.28 - 9.36	9.36 - 9.43

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Wed, 13 May 2026
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases - TradingView

Wed, 13 May 2026
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

Wed, 13 May 2026
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary - TradingView

Wed, 13 May 2026
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance UK

Wed, 13 May 2026
Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Moomoo

Wed, 13 May 2026
Upstream Bio, Inc. (UPB) Eps Diluted (TTM) - Zacks Investment Research

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	54 (M)
Held by Insiders	3.459e+007 (%)
Held by Institutions	14.8 (%)
Shares Short	4,750 (K)
Shares Short P.Month	0 (K)

EPS	-1.6017e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-6 %
Return on Assets (ttm)	911.2 %
Return on Equity (ttm)	-24 %
Qtrly Rev. Growth	2.85e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-133 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	3.02e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.